KRAS G12C inhibitor 18 is a potent and orally activeKRAS G12Cinhibitor. Anti-tumor activities^[1].

KRAS G12C inhibitor 18 (compound 34) inhibits the growth of many KRas G12C mutant tumor cell lines (such as H358, SW1436, MiaPaca-2 cells, etc.)^[1].

KRAS G12C inhibitor 18 exhibits a dose dependent inhibiton of pERK and active KRas after a single dose treatment from 12.5 to 100 mg/kg at 8 hours^[1].
KRAS G12C inhibitor 18 (30 mg/kg; p.o.; twice daily) exhibits anti-tumor growth activity in lung cancer H358 xenograft mouse model^[1].

510.97

C₂₅H₂₀ClFN₄O₃S

2649788-45-2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.